近段时间,医药行业尤其是创新药领域热度高涨,曾经因壁垒较高而曲高和寡的医药研究成为香饽饽,甚至连部分非医药研究员也临时跨界研究医药;创投圈开始聚焦关注创新药,58同城创始人姚劲波拟用6.62亿元收购易明医药控股权;此外公募基金年度排行榜旧貌换新颜,最新排在前列的基金多和重仓创新药有关。但在一派热闹表象的背后,创新药公司真正的投资价值和产业潜力才是题中要义。从二级市场来看,截至6月9日收盘,汇总统计...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.